If the two-dose vaccine is approved, it would be the fourth COVID-19 vaccine available in the United States
MONDAY, March 8, 2021 (HealthDay News) — AstraZeneca says it will file for emergency use authorization of its COVID-19 vaccine in the United States after it gets the results of a clinical trial within the next few weeks.
If the two-dose vaccine is approved by the U.S. Food and Drug administration, it would be the fourth COVID-19 vaccine available in the United States. Upon FDA approval, AstraZeneca plans “to deliver roughly 50 million doses instantly to Americans,” Ruud Dobber, the company’s executive vice president, told CBS News on Friday.
The AstraZeneca vaccine is already being used internationally, after being approved by the European Union, the United Kingdom, and the World Health Organization. The three currently approved vaccines in the United States are from Moderna and Pfizer — both require two doses — and a one-dose vaccine from Johnson & Johnson.
Dobber also told CBS News “we’re very hopeful” that the AstraZeneca vaccine is “very effective against the U.K. variant” of the coronavirus, and that the company is “developing a potential new vaccine in case our current vaccine is not as effective as we were hoping for.”
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
Trends Reported in Vaccination Coverage for Adolescents for 2025
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists
Youth Suicide Risk Linked to Community Firearm Violence
Social Media Warnings Could Discourage Use Among Teens, Young Adults
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens